Virus de hepatitis B y C en lupus eritematoso sistémico. Presentación de casos.
Keywords:
Lupus Eritematoso Sistémico, Virus Hepatitis C y BAbstract
El lupus eritematoso sistémico (LES) es una enfermedad autoinmune caracterizada por múltiples autoanticuerpos patogénicos tales como anti-ADN (nefritis), anticardiolipina (trombosis) y anti-Ro (bloqueo aurículo-ventricular). En la etiología específica del LES intervienen numerosos factores genéticos y ambientales. El Virus de Hepatitis C (VHC) y el Virus de Hepatitis B (VHB) pueden representar un estímulo crónico para la expansión de células B en los pacientes con LES. Pocos estudios se han publicado sobre la prevalencia VHC y VHB en sujetos con lupus. Mientras algunos estudios encuentran una alta prevalencia, otros no los confirman. Existen datos que indican que la ocurrencia del AgsHB y anticuerpo contra el VHC no se encuentra incrementada en los pacientes con lupus, comparada con grupo control de la misma área geográfica. Se presentan dos pacientes con diagnóstico de lupus eritematoso sistémico y presencia de virus de hepatitis B y C positivos por técnica de UMELISA® de tercera generación.
Downloads
References
-Battagliotti CA, Kilstein J, Gentiletti AA, Pons Estel B. Lupus Eritematoso Sistémico.
Aspectos clínicos y terapéuticos. 2da. ed. Buenos Aires: Ed: CB Eitores; 1998. p. 187-94.
-Petri M. La cohorte de Lupus de Hopkins. Puesta al día. Clínic Rheumatic Disease of
North America (Edición Española). 2000;(2):203-17.
-Font J. Khamashta M, Vilardell M. Lupus Eritematoso Sistémico. Segunda parte, Capítulo VI. Barcelona: Ed. MRA, S.L; 1996. p. 73-239.
-Hernández Muñiz Y, Dedieu Montero D, Pozo Abreu S M, Carrillo Reyes C, Mederos Castellanos A. Factores asociados a la aparición de aterosclerosis subclínica en lupus eritematoso sistémico. Rev. Cubana de Reumatol [Internet]. 2022 Abr [citado 2024 Nov 27]; 24(1): Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1817-59962022000100004&Ing=es. Epub01-Abr-2022.
-Mercado U, Avendaño-Reyes M, Araiza-Casillas R, Díaz-Molina R. Prevalencia de anticuerpos contra virus de hepatitis C y B en pacientes con lupus eritematoso sistémico. Rev Gastroenterol Mex. 2005; 70(4):399-401.
-Afonso AM, Jiang J, Penin F, Tareau C, Samuel D, Petit MA et al. Nonrandom distribution of hepatitis C virus quasispecies in plasma and peripheral blood mononuclear cell subsets. J Virol 1999; 73: 9213-9221.
-Pascual M, Perrin L, Giostra E, Schifferli JA. Hepatitis C virus in patients with cryoglobulinemia type II. J Infect Dis 1990; 162: 569-570.
-Cacoub P, Poynard Th, Ghillani P, Charlotte F, Olivi M, Piette JC et al. Extrahepatic manifestations of chronic hepatitis C. Arthritis Rheum 1999; 42: 2204.
-Pawlotsky JM, Ben Yahia M, Andre C, Voisin MC, Intrator L, Roudot-Thoraval F et al. Immunological disorders in C virus chronic active hepatitis: a prospective case-control study. Hepatology 1994; 19: 841-848.
- Rivera J, García-Monforte A, Millan J. Extrahepatic symtoms as presenting manifestations of hepatitis C virus infection. J Clin Rheumatol 1999; 5: 268-272.
-Ramos-Casals M, García-Carrasco M, Cervera R, Rosas J, Trejo O, de la Red G et al. Hepatitis C virus infection mimicking Sjögren’s syndrome. Clinical and immunologic
description of 35 cases. Medicine (Baltimore) 2001; 80: 1-8.
-Baffoni L, Frisoni M, Miniero R. True positive anti-HCV tests in rheumatoid arthritis. Br J Rheumatol 1992; 32: 349-350.
-Deny P, Bonacorsi S, Guillevin L. Association between hepatitis C virus and polyarteritis nodosa. Clin Exp Rheumatol 1992; 10: 319.
-Marchesoni A, Battafarano N, Podico M, Tosi S. Hepatitis C virus antibodies and systemic lupus erythematosus. Clin Exp Rheumatol 1995; 13: 267.
-Kowdley KV, Subler DE, Scheffel J, Moore B, Smith H. Hepatitis C virus antibodies in systemic lupus erythematosus. J Clin Gastroenterol 1997; 25: 437-439.
-Abu-Shakra M, El-Sana S, Margalith M, Sikuler E, Neumann L, Buskila D et al. Hepatitis B and C viruses serology in patients with SLE. Lupus 1997; 6: 543-544.
-Karakoç Y, Dilek K, Gullulu M, Yavuz M, Ersoy A, Akalyn H et al. Prevalence of hepatitis C virus antibody in patients with systemic lupus erythematosus. Ann Rheum Dis 1997; 56: 570-571.
-Yamabe H, Johnson RJ, Gretch DR, Fukushi K, Osawa H, Miyata M et al. Hepatitis C virus infection and membranoproliferative glomerulonephritis in Japan. J Am Soc Nephrol 1995; 6: 220-223.
-Dalekos GN, Kistis KG, Boumba DS, Voulgari P, Zervou EK, Drosos AA et al. Increased incidence of anticardiolipin antibodies in patients with hepatitis C is not associated with aetiopathogenetic link to antiphospholipid syndrome. Eur J Gastroenterol Hepatol 2000; 12: 67-74.
-Cacoub P, Lunel F, Huong LT. Polyarteritis nodosa and hepatitis C virus infection. Ann Intern Med 1992; 116: 605.
-Ramos-Casals M, Font J, García-Carrasco M, Cervera R, Jiménez S, Trejo O et al. Hepatitis C Virus Infection Mimicking Systemic Lupus Er ythematosus. Study of hepatitis C virus infectionin a series of 134 Spanish patients with systemic lupus erythematosus. Arthritis Rheum 2000; 43: 2801-2806.
-Wang S, Chen Y, Xu X, Hu W, Shen H and Chen J. Prevalence of hepatitis B virus and hepatitis C virus infection in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Oncotarget, 2017, Vol. 8, (No. 60), pp: 102437-102445.
-Schoggins JW, Rice CM. Interferon-stimulated genes and their antiviral effector functions. Curr Opin Virol. 2011; 1:519–525.
-Pei RJ, Chen XW, Lu MJ. Control of hepatitis B virus replication by interferons and Toll-like receptor signaling pathways. World J Gastroenterol. 2014; 20:11618–11629.
-Linker-Israeli M, Deans RJ, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR. Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in
pathogenesis. J Immunol. 1991; 147:117–123.
-Hosel M, Quasdorff M, Wiegmann K, Webb D, Zedler U, Broxtermann M, Tedjokusumo R, Esser K, Arzberger S, Kirschning CJ, Langenkamp A, Falk C, Buning H, et al. Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection. Hepatology. 2009; 50:1773–1782.
-James WH. A potential explanation of the reported low prevalence of hepatitis B virus infection in patients with systemic lupus erythematosus. Rheumatol Int. 2012; 32:835.
-Yu MW, Chen CJ. Elevated serum testosterone levels and risk of hepatocellular carcinoma. Cancer Res. 1993; 53:790.
-Yuan JM, Ross RK, Stanczyk FZ, Govindarajan S, Gao YT, Henderson BE, Yu MC. A cohort study of serum testosterone and hepatocellular carcinoma in Shanghai, China. Int J Cancer. 1995; 63:491–493.
-World Health Organization. Global hepatitis report 2024: Action for Access in low-and middle-income contries. Ed: OMS. ISBN: 978-92-4-009167-2.
-Gonzalez Valdés M. Anuario Estadístico de Salud de Cuba. Rev Méd Electrón [Internet]. 2023 [citado 28 Nov 2024]; 38(5). Disponible en: http://revmedicaelectronica.sld.cu/index.php/rme/article/view/1720.
- García Carrasco M y col. El virus de la hepatitis C en el lupus eritematoso sistémico y el síndrome antifosfolipídico. Rev Esp Reumatol. ISSN 0304-4815, Vol. 28(8), 2001, págs, 330-340.
-M. Mubashir Ahmed, Seth Mark Berney, Robert E. Wolf, Michelene Hearth-Holmes, Samina Hayat, Eisha Mubashir, Henri Vanderheyde, Wun-Ling Chang, John W. King. Prevalence of Active Hepatitis C Virus Infection in Patients with Systemic Lupus Erythematosus, The American Journal of the Medical Sciences. [Internet]. 2006 [citado 2024 Nov 28]; 331(5). Disponible en: https://doi.org/10.1097/00000441-200605000-00003.
-Martínez Delgado JF, Pérez de Alejo Rodríguez M, Sverio Martínez E. infecciones en el lupus eritematoso sistémico. Acta Méd Centro [Internet]. 2010 [citado 29 Nov 2024]; 4(4). Disponible en: https://revactamedicacentro.sld.cu/index.php/amc/article/view/532.
Downloads
Published
How to Cite
Issue
Section
License
Warning of rights of author
The authors that publish in this journal agree with the following terms:
The authors conserve the rights of author and concede to the journal the right of the first publication, fulfilling with the license Creative Commons Attribution License that allows to others share the work with recognition of the authorship of their articles, and the initial publication in this journal.
The authors can establish separately additional agreements for the no exclusive distribution of the version of the work published in the journal (for example, situate it in an institutional repository, in a personal blog or publish it partial or totally in a book), with a recognition of their initial publication in this journal.
To be able to send the manuscript or part of him passed three months of published, for his evaluation to other publishers, identifying it or not with the same title; whenever allusion is made to our journale and know it the new publisher.
The publishing committee of the Cuban Journal of Rheumatology authorizes to other publishers, to reproduce the articles published in our magazine, whenever it indicate the origin of the same.
The authors should send a document in Office Word application format through the electronic address of the magazine with a similar format to that we include next:
---------------------------------------------------------------------------------------------------------------------
Statement of authorship and cede of articles for the publication of the scientific work in the Cuban Journal of Rheumatology
Date:
Those who subscribe certify that are the authors of the work:
Of this form communicate the originality of our article clearing that the concepts and knowledges of other authors that have included in the text of the article, have been quoted properly in the bibliography.
We do proof besides that the article in question is original and has not been published, total neither partially, in another journal.
To be approved for his publication in the Cuban Journal of Rheumatology, do secession of the rights of publication to the same one through the method that realizes it usually.
In front of any catchword that exist by the article that send to evaluate, relieve of of the responsibility to the Cuban Journal of Rheumatology holding us responsible with all the difficulties that can berelated by any situation.
We include to continuation the name and the signature of all authors and collaborators of this article.
Name: Signature:
